New Delhi, May 15 (UNI) Leader in oncology medical testing market, Dabur OncQuest today announced a tool for confirmation of drug resistance in Chronic Myelogenous Leukemia (CML) patients.
Developed after a sequence of research in the Dabur OncQuest in-house laboratory, CML Quest (IRMA) is the first of its kind of test that is available globally.
The test is available only at the centres of Dabur OncQuest pan-India and Nepal, a statement said adding that it helps clinicians to make critical decision on therapeutic front.
''The product was developed keeping in mind the enormous cost and time involved in undergoing numerous treatments. With the roll out of CML Quest (IRMA), OncQuest lives up to its mission of introducing scientifically advanced cost effective molecular diagnostic algorithm,'' Dabur Pharma General Manager Aditya Burman said.
UNI
Developed after a sequence of research in the Dabur OncQuest in-house laboratory, CML Quest (IRMA) is the first of its kind of test that is available globally.
The test is available only at the centres of Dabur OncQuest pan-India and Nepal, a statement said adding that it helps clinicians to make critical decision on therapeutic front.
''The product was developed keeping in mind the enormous cost and time involved in undergoing numerous treatments. With the roll out of CML Quest (IRMA), OncQuest lives up to its mission of introducing scientifically advanced cost effective molecular diagnostic algorithm,'' Dabur Pharma General Manager Aditya Burman said.
UNI
Oneindia Login